Last reviewed · How we verify

Therapy of hemorrhagic disease of the newborn — Treatment Landscape & Competitive Intelligence

Therapy of hemorrhagic disease of the newborn (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Therapy of hemorrhagic disease of the newborn, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vitamin K1 Phytonadione Pfizer Inc. Vitamin K [EPC] Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Therapy of hemorrhagic disease of the newborn

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Therapy of hemorrhagic disease of the newborn:

Cite this brief

Drug Landscape (2026). Therapy of hemorrhagic disease of the newborn — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/therapy-of-hemorrhagic-disease-of-the-newborn. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing